ACADIA Pharmaceuticals Q2 Earnings Call Highlights
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Wed, 5 August 2026
What it is about
Catherine Owen AdamsThomas GarnerMark SchneyerPharmaceuticals IncDrug AdministrationAcadia PharmaceuticalsDevelopment Elizabeth ThompsonCenters Of ExcellenceEuropean CommissionHead Of ResearchGermanyCalifornia, United StatesJapaneseJapanSan Diego, California, United States
Who published it, and when
How it spread - 1 original report
Wed, 5 August 2026
1 report- themarketsdaily.com15:04first to report
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson’s disease psychosis treatment NUPLAZID increased. Chief Executive Officer Catherine Owen Adams said the quarter reflected strong commercial execution across both brands, while the company also advanced its […]